Pin Xiang, BA
Pharm.D Candidate
University of California, San Francisco
School of Pharmacy
3333 California Street
Suite 420
San Francisco,
CA
USA
94118
Papers:
3G-4
ERLOTINIB, AFATINIB, AND CISPLATIN/PEMETREXED FOR FIRST-LINE TREATMENT OF ADVANCED EGFR-MUTATION POSITIVE NON-SMALL CELL LUNG CANCER: VALUE-OF-INFORMATION ANALYSIS
Student?
yes
SMDM Member?
yes